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Abstract 
Background: Left ventricular ejection fraction (LVEF) trajectories and functional recovery with current heart failure 
(HF) management is increasingly recognized. Type 2 diabetes mellitus (T2D) leads to a worse prognosis in HF patients. 
However, it is unknown whether T2D interferes with LVEF trajectories. The aim of this study was to prospectively 
assess very long‑term (up to 15 years) LVEF trajectories in patients with and without T2D and underlying HF.
Methods: Ambulatory patients admitted to a multidisciplinary HF clinic were prospectively evaluated by scheduled 
two‑dimensional echocardiography at baseline, 1 year, and then every 2 years afterwards, up to 15 years. Statistical 
analyses of LVEF change with time were performed using the linear mixed effects (LME) models, and locally weighted 
error sum of squares (Loess) curves were plotted.
Results: Of the 1921 patients, 461 diabetic and 699 non‑diabetic patients with LVEF < 50% were included in the 
study. The mean number of echocardiography measurements performed in diabetic patients was 3.3 ± 1.6. Early LVEF 
recovery was similar in diabetic and non‑diabetic patients, but Loess curves showed a more pronounced inverted 
U shape in diabetics with a more pronounced decline after 9 years. LME analysis showed a statistical interaction 
between T2D and LVEF trajectory over time (p = 0.009), which was statistically significant in patients with ischemic 
etiologies (p < 0.001). Other variables that showed an interaction between LVEF trajectories and T2D were male sex 
(p = 0.04) and HF duration (p = 0.008).
Conclusions: LVEF trajectories in T2D patients with depressed systolic function showed a pronounced inverted U 
shape with a marked decline after 9 years. Diabetic cardiomyopathy may underlie the functional decline observed.
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Background
Heart failure (HF) is a multidimensional syndrome with 
a wide variety of symptoms and signs associated with 
cardiac functional and structural abnormalities, and car-
ries a high morbidity and mortality [1, 2]. Patients with 
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risk of developing HF compared to non-diabetic patients, 
and 15–25% of patients with HF have diabetes. This risk 
of HF remains high despite achieving control of other 
major cardiovascular risk factors [3–5]. Moreover, the 
presence of T2D contributes to worse outcomes in HF. 
Patients with T2D are more likely to be hospitalized for 
HF, to be re-admitted for HF, and have a higher risk of 
cardiovascular and all-cause mortality than those with-
out diabetes and HF [6, 7]. Insulin resistance and hyper-
glycemia, the key central metabolic disturbances in T2D, 
lead to specific structural and metabolic abnormalities 
that adversely affect myocardial function [8].
Advances in HF treatment including drug therapy, 
devices, coronary revascularization, and valvular repair 
are responsible for systolic function improvement in 
patients with depressed left ventricular ejection frac-
tion (LVEF) [3, 9], which might be maintained for a 
decade. We recently described the dynamic long-term 
trajectory of LVEF in a real-life cohort of HF patients 
with depressed systolic function of diverse etiology. Data 
from this study revealed that LVEF trajectory is highly 
variable dependent upon etiology, HF duration, and 
sex, but in general showed a significant improvement at 
1 year, with an LVEF rise up to decade and a slow decline 
thereafter [10]. It remains unclear whether the presence 
of T2D interferes with the improvement and trajectories 
of LVEF.
Accordingly, the aim of the present study was to assess 
very long-term (up to 15 years) LVEF trajectories in T2D 
HF patients (from ischemic and non-ischemic etiologies), 




This study is a T2D-focused post hoc sub analysis of a 
previously reported cohort [10]. All consecutive ambu-
latory patients referred to a structured multidisciplinary 
HF clinic of a university hospital between August 2001 
and December 2015, regardless of etiology, were con-
sidered for the study. During the 15-year period, clinical 
pathways and referral geographical area, encompassing 
~ 850,000 inhabitants in the northern Barcelona Metro 
Area, remained stable. The criteria for referral to the HF 
clinic were HF with at least one hospitalization and/or 
depressed systolic function [10, 11]. Patients were treated 
according to a unified protocol. During the baseline visit, 
patients provided written consent for the use of their 
clinical data for research purposes.
Inclusion criteria
The main inclusion criteria for this study were having 
had at least two echocardiography measurements, one at 
baseline and the other during follow-up. Patients under-
going heart transplantation or cardiac resynchronization 
therapy after the second echocardiography were cen-
sored at the time of the intervention. The study was per-
formed in compliance with the law protecting personal 
data in accordance with the international guidelines on 
clinical investigation of the World Medical Association’s 
Declaration of Helsinki.
Study outcome and follow‑up
The primary outcome of the study was prospectively 
assess very long-term (up to 15 years) LVEF trajectories 
in patients with and without T2D and underlying HF. 
All patients were seen regularly during follow-up vis-
its at the HF clinic according to their clinical needs and 
treated according to a unified protocol [10, 11]. Follow-
up visits included a minimum of 1 visit with a nurse 
every 3 months and 1 visit with a physician (cardiologist, 
internist, or family physician) every 6 months, as well as 
optional visits with specialists in geriatrics, psychiatry, 
and rehabilitation. During the baseline visit, patients pro-
vided written consent for the use of their clinical data for 
research purposes [10, 11].
Echocardiogram studies
LVEF was prospectively evaluated at baseline and at 1, 3, 
5, 7, 9, 11, 13, and 15 years of follow-up using two-dimen-
sional echocardiography by image expert cardiologists 
[10]. LVEF was obtained from apical two- and four-
chamber views and was calculated using the Simpson’s 
method. All echocardiograms were revised for accuracy 
by expert staff.
T2D diagnosis
A diagnosis of T2D was made when at least one of the 
following criteria was met: (1) a diagnosis of T2D was 
previously established and recorded in the patient’s elec-
tronic History; (2) fasting plasma glucose ≥ 126 mg/dL or 
hemoglobin A1C ≥ 6.5% identified by laboratory testing 
[12]; or (3) had a current prescription for oral hypoglyce-
mic medication or insulin.
Statistical analysis
Categorical variables were expressed as absolute num-
bers and percentages. Continuous variables were 
expressed as the mean (standard deviation) or median 
(quartiles Q1 to Q3) according to normal or non-normal 
distributions. Normal distribution was assessed with a 
normal Q–Q plot. Locally weighted error sum of squares 
(Loess) curves were plotted for diabetic and non-diabetic 
patients and for pre-specified study subgroups. Loess 
regression is a non-parametric approach developed in 
1988 [13]. Loess curves are useful for observing a trend 
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or relationship for non-linear data observed over time. 
Loess moves along the dataset looking at chunks at a 
time, fitting a set of local regression lines computed on 
observed data (missing values are omitted) and con-
necting these lines to make a smooth line. Missing data 
due to loss to follow-up was assumed to be at random as 
there was no evidence that not attending the scheduled 
visit had anything to do with LVEF. Locally weighted 
regression is based on a weight function, which gives the 
greatest weight to observations that are closest to the 
focal observation. Statistical analyses of LVEF change 
over time were performed using the linear mixed effects 
(LME) model, which takes into account the group level 
structure in the data by simultaneous assessing effects 
within and across groups. LME models incorporate both 
fixed effects and random effects [14] and describe the 
relationship between a response and covariates that have 
been observed along with the response [15]. In this study, 
LME models were developed to evaluate and compare 
the effect of time on LVEF change for diabetic and non-
diabetic patients and for pre-specified subgroups accord-
ing to HF etiology, HF duration at baseline and sex. We 
hypothesized that there are important individual-level 
effects and that patients have similar rates of change over 
time. Thus, we fitted the “Random Intercept LME mod-
els,” where the measured value of LVEF is assumed to 
have a set of parameters fixed across individuals, includ-
ing a specific random effect per individual. Because the 
form of the Loess curves suggested at least a quadratic in 
time, all LME models included both the linear term time 
and the quadratic time ‘timeˆ2’ as fixed effects. By add-
ing the quadratic term ‘timeˆ2’ to the models, we evalu-
ated whether the effect of time significantly changed over 
time. The Wald Chi-squared test was applied to evalu-
ate the accuracy of the estimates of the effect of time on 
LVEF values. Comparisons of LVEF between groups were 
also performed at every timepoint of the study using 
the paired t-test. Comparisons between included and 
excluded patients and between alive and dead patients 
were performed using the Student’s t-test, Mann–Whit-
ney U test, or Chi-squared test as appropriate. Multi-
variable Cox regression analyses were performed with 
all-cause death and the composite all-cause death or 
HF hospitalization as the dependent variables and age, 
sex, diabetes mellitus, baseline LVEF, ischemic etiol-
ogy and NYHA functional class as covariates. Recurrent 
HF-related hospitalizations were analyzed as crude inci-
dence rates (expressed as number of hospitalizations per 
100 patient-years) and by multivariable binomial nega-
tive regression, expressed as incidence rate ratios (IRRs). 
Only for the later analyses, out-of-hospital death due to 
HF was considered as an additional event. In a sensitiv-
ity analysis the influence of diabetic control-based on 
2662 measurements of HbA1c—on LVEF trajectory and 
outcomes was also performed within diabetic patients. 
Optimal glycemic control was considered when median 
values of HbA1c for each patient were ≤ 7.5%.
Statistical analyses were performed using SPSS 24 
(SPSS, Inc., Chicago, IL, USA) and R (A Language and 
Environment for Statistical Computing) by the R Core 
Team (2017; R Foundation for Statistical Computing, 
Vienna, Austria). For LME models, we used the nlme R 
package (version 3.1-131.1). Two-sided p < 0.05 was con-
sidered statistically significant. The data, analytic meth-
ods, and study materials will not be made available to 
other researchers for the purposes of reproducing the 
results or replicating the procedure. J.L. had full access to 
all data in the study and takes responsibility for its integ-
rity and the data analysis.
Results
A total of 1921 patients were admitted to the HF clinic 
from August 2001 to December 2015, and 1656 had an 
LVEF < 50%. After the exclusion criteria were applied, 
1160 patients had a minimum of two LVEF measure-
ments and comprised the study population [10]. Focus-
ing on T2D patients, a range of 2 to 9 echocardiograms 
were performed per patient, in a total of 1534 patients 
as shown in Additional file 1: Figure S1. The mean num-
ber of echocardiograms performed in T2D patients 
(3.3 ± 1.6) was less than that performed in non-diabet-
ics (3.8 ± 1.8; p < 0.001) and follow-up was also signifi-
cantly shorter in T2D patients (5.8 ± 3.7 vs. 7 ± 4.1 years; 
p < 0.001).
Table 1 shows the clinical, biochemical, and echocardi-
ographic characteristics of the studied cohort and treat-
ment during follow-up based on the presence or absence 
of T2D. The main etiology in diabetic patients was 
ischemic heart disease (64.6%) followed by dilated car-
diomyopathy (12.1%). Medical treatment was optimized 
according to international guidelines. Although diabetic 
patients received less angiotensin-converting enzyme 
inhibitor/angiotensin II receptor blockers treatment; in 
contrast they received more mineralocorticoid receptor 
antagonist, loop diuretic, digoxin, and ivabradine treat-
ments. Comparison between included and not included 
patients due to lack of a second echocardiogram to 
address group bias, has been reported elsewhere [10]. No 
statistical differences were found in the variables mostly 
associated with LVEF dynamics such as sex, etiology, 
baseline LVEF, and HF duration. There was also no statis-
tically significant difference in the prevalence of diabetes: 
included 461 (40%), excluded 118 (43.7%) (p = 0.23).
Baseline characteristics of the study population strati-
fied by HF etiology and diabetic status are presented in 
Additional file 2: Table S1. Co-morbidities such as anemia 
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Table 1 Demographic, clinical, and therapeutic characteristics of patients at baseline and treatments during follow-up
Data in mean ± SD, median (IQR) or n (%)
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, BMI body mass index, CRT cardiac resynchronization therapy, eGRF estimated 
glomerular renal filtration (CKD-EPI equation), F-U follow-up, HF heart failure, ICD implantable cardiac defibrillator, LBBB left bundle branch block, LVEF left ventricular 
ejection fraction, LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic diameter, MRA mineralocorticoid receptor antagonist, NYHA New 
York Heart Association, NTproBNP N-terminal pro-brain natriuretic peptide
a According to W.H.O. criteria (< 13 g/dL in men and < 12 g/dL in women)
b eGFR (CKD-EPI equation) < 60 ml/min/1.73 m2
Diabetics Non‑diabetics p‑value N
N = 461 N = 699
Age, years 66.4 ± 10.5 64 ± 13.2 0.001 1160
Male 338 (73.3) 549 (78.5) 0.04 1160
White 459 (99.6) 692 (99.0) 0.20 1160
Etiology < 0.001 1160
 Ischaemic heart disease 298 (64.6) 361 (51.6)
 Dilated cardiomyopathy 56 (12.1) 105 (15.0)
 Hypertensive 33 (7.2) 48 (6.9)
 Alcohol 16 (3.5) 52 (7.4)
 Drugs 7 (1.5) 27 (3.9)
 Valvular 23 (5.0) 49 (7.0)
 Other 28 (6.1) 57 (8.2)
Previous AMI 238 (51.6) 306 (43.8) 0.009
HF duration, months 7 (2–39) 6 (1–41) 0.10 1160
NYHA class 0.001 1160
 I 14 (3.0) 46 (6.6)
 II 318 (60.0) 499 (71.4)
 III 125 (27.1) 152 (21.7)
 IV 4 (0.9) 2 (0.3)
LVEF, % 30.4 ± 8.4 30.3 ± 8.6 0.96 1160
LVEDD, mm 60.6 ± 7.9 61.8 ± 8.6 0.02 1043
LVESD, mm 48.4 ± 9.4 49.8 ± 9.6 0.02 1027
Hypertension 333 (72.2) 380 (54.4) < 0.001 1160
Anemiaa 232 (52.3) 248 (36.3) < 0.001 1127
Renal  insufficiencyb 239 (52.2) 249 (36.1) < 0.001 1148
Atrial fibrillation/flutter 80 (17.4) 123 (17.6) 0.92 1160
LBBB 60 (13.0) 95 (13.6) 0.78 1160
Heart rate, bpm 72.2 ± 13.6 69.6 ± 15.1 0.003 1160
Blood pressure, mmHg 126.5 ± 21.9 124.8 ± 21.6 0.19 1160
BMI, kg/m2 27.7 (25–31.2) 26.5 (23.9–29.7) < 0.001 1156
NTproBNP, ng/L 1825 (808–4363) 1530 (611–3344) 0.01 714
HF treatments (F‑U), n (%)
 ACEI or ARB 421 (91.3) 663 (94.8) 0.02 1160
 Beta‑blocker 436 (94.6) 658 (94.1) 0.75 1160
 MRA 333 (72.2) 445 (63.7) 0.002 1160
 Loop diuretic 441 (95.7) 621 (88.8) < 0.001 1160
 Digoxin 213 (46.2) 264 (37.8) 0.004 1160
 Ivabradine 113 (24.5) 122 (17.5) 0.003 1160
 Sacubitril/valsartan 14 (3.0) 30 (4.3) 0.27 1160
 CRT 23 (5.0) 45 (6.4) 0.30 1160
 ICD 62 (13.4) 109 (15.6) 0.31 1160
Antidiabetic treatments
 Oral drugs baseline 248 (53.8) 461
 Insulin baseline 175 (38.0) 461
 Oral drugs F‑U 367 (79.6) 461
 Insulin F‑U 305 (66.2) 461
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hypertension, and renal insufficiency were more preva-
lent in diabetic patients, both from ischemic and non-
ischemic etiologies. Differences between diabetic and 
non-diabetic patients were generally similar in ischemic 
and non-ischemic etiologies, except regarding the use of 
loop diuretics and cardiac devices. Mean LVEF values in 
diabetic patients were 30.4% ± 8.4 (n = 461), 37.9% ± 11.6 
(n = 417), 40.7% ± 12.3 (n = 304), 41.9% ± 12.4 (n = 156), 
43% ± 13.2 (n = 92), 42.9% ± 12.4 (n = 53), 42% ± 11.2 
(n = 34), 39.2% ± 11 (n = 17), and 40.6% ± 11.7 (n = 12) 
at baseline and 1, 3, 5, 7, 9, 11, 13, and 15 years, respec-
tively. Dynamic trajectories of LVEF based on the 
presence or absence of T2D are illustrated in Fig.  1. 
Paired data comparisons showed statistical differences 
between baseline and 1  year (p < 0.001), and between 1 
and 3  years (p < 0.001; Additional file  2: Table  S2). As a 
whole, Loess splines of long-term LVEF trajectories in 
diabetic patients showed a more pronounced inverted 
U shape with a marked rise in LVEF during the first year 
(slightly lower than that of non-diabetics), followed by a 
more pronounced and earlier LVEF decline (p for trajec-
tory < 0.001 for both groups; p for interaction between 
LVEF trajectory and diabetes = 0.009).
Figure  2a, b shows LVEF trajectories relative to the 
etiology of HF, ischemia versus non-ischemia. Long-
term LVEF decline was more apparent in T2D ischemic 
patients with HF (p for interaction < 0.001) (Fig.  2a). 
An interaction between T2D and LVEF trajectory in 
patients with longer HF duration (p = 0.008; Additional 
file  3: Figure  S2A; Additional file  4: Figure  S2B) and in 
males (p = 0.04; Additional file  5: Figure  S3A) was also 
observed. In T2D women, no differences were observed 
Fig. 1 Loess spline curves of long‑term LVEF trajectories. LVEF 
trajectory comparison between diabetic (orange) vs. non‑diabetic 
(blue) patients. P for trajectory changes on LVEF < 0.001 for both 
groups. P for comparison between groups (interaction between 
trajectory changes and diabetes) = 0.009. Shaded regions displayed 
around curves represent the confidence interval at level = 0.95
Fig. 2 Loess spline curves of long‑term LVEF trajectories based on etiology. a Patients from ischemic aetiology of HF; diabetic (orange) vs. 
non‑diabetic (blue) patients. P value for trajectory changes on LVEF < 0.001 for both groups. P for comparison between groups (interaction between 
trajectory changes and diabetes) < 0.001. Shaded regions displayed around curves represent the confidence interval at level = 0.95. b Patients from 
non‑ischemic aetiologies. P value for trajectory changes on LVEF < 0.001 for both groups. P for comparison between groups (interaction between 
trajectory changes and diabetes) = 0.18. Shaded regions displayed around curves represent the confidence interval at level = 0.95
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in the dynamic trajectories of LVEF (Additional file  6: 
Figure S3B).
Focusing on diabetic patients (Fig. 3a–c), non-ischemic 
patients showed a significantly higher LVEF upslope 
during essentially the entire trajectory (p < 0.001) com-
pared to ischemic patients (Fig. 3a). A more pronounced 
increase in LVEF during the first year and absence of 
decrease at the end of follow-up was observed in new-
onset HF patients (≤ 12  months) compared to patients 
with longer HF duration at the baseline visit (Fig.  3b; 
p < 0.001); and women showed better LVEF improve-
ment than men during nearly all trajectories with a more 
pronounced inverted U-shape pattern (Fig. 3c; p = 0.03); 
finally, for those patients with available measurements 
Fig. 3 Loess spline curves of long‑term LVEF trajectories in diabetic patients based on clinical modifiers. a Aetiology: ischemic (blue) vs. 
non‑ischemic (yellow) aetiology. P for trajectory changes on LVEF < 0.001 for both groups. P for comparison between groups < 0.001. Shaded 
regions displayed around curves represent the confidence interval at level = 0.95. b HF Duration: ≤ 12 months (blue) vs. > 12 months (yellow). P 
value for trajectory changes on LVEF < 0.001 for both groups. P for comparison between groups < 0.001. Shaded regions displayed around curves 
represent the confidence interval at level = 0.95. c Sex: women (blue) vs. men (yellow). P for trajectory changes on LVEF < 0.001 for both sexes. P for 
comparison between sexes < 0.001. Shaded regions displayed around curves represent the confidence interval at level = 0.95. d Optimal (blue) vs. 
non‑optimal glycemic (yellow) control. P for trajectory changes on LVEF < 0.001. P for comparison between glycemic control groups 0.35. Shaded 
regions displayed around curves represent the confidence interval at level = 0.95
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of HbA1c, no differences in LVEF trajectories were 
observed based on the optimal/non-optimal glycemic 
control according to the predefined definition (Fig.  3d; 
p = 0.32).
Causes of death according to the presence of diabetes 
are shown in Additional file  2: Table  S3. As expected, 
mortality was higher in diabetic patients, mainly due to 
HF progression. Cox regression analyses for all-cause 
death and for the composite end-point of all-cause death 
or HF-related hospitalization are shown in Additional 
file  2: Table  S4. Furthermore, a worse prognosis was 
seen in patients with T2D and ischemic heart disease, 
while non-diabetic patients with non-ischemic etiology 
showed the best prognosis (Additional file 7: Figure S4A 
and Additional file  8: Figure S4B). Remarkably, diabetic 
patients with non-ischemic etiology had a slightly worse 
prognosis than non-diabetic patients with ischemic etiol-
ogy. So, the presence of T2D was associated with a higher 
morbidity and mortality, regardless of whether HF was 
of ischemic or non-ischemic etiology. Within diabetic 
patients, in a sensitivity analysis, those with optimal gly-
cemic control showed better prognosis than those with 
non-optimal control (HR 0.75 [0.55–1.02], p = 0.07 for 
all-cause death and HR 0.75 [0.57–0.97], p = 0.03 for 
the composite end-point respectively, after adjustment 
by age, sex, baseline LVEF, ischemic etiology and NHYA 
functional class. Finally, diabetic patients showed a dou-
ble number of recurrent admissions (23.4 vs. 11.2 per 
100 patient-years, p < 0.001). In multivariable negative 
binomial regression analysis, adjusted IRR was 2.0 (1.15–
3.48), p = 0.02. Within diabetic patients we did not find 
significant relationship between the degree of glycemic 
control and recurrent HF admissions (IRR 0.69 [0.30–
1.58], p = 0.37).
Discussion
Large epidemiological studies have confirmed that T2D is 
an independent risk factor for the development of HF [3]. 
It is known that diabetic patients with HF have a higher 
all-cause mortality and cardiovascular mortality than 
non-diabetic HF patients [5, 6]. Moreover, following the 
first HF hospitalization, the incidence of new-onset dia-
betes was around 2% per year, rising to 3% after 5 years 
of follow-up, and it was associated with an increased risk 
of death in established HF patients [16]. However, little 
is known about the comparison of LVEF trajectories over 
time between diabetic and non-diabetic patients. Focus-
ing on diabetic patients, the present study expands the 
prospective assessment of LVEF trajectories in a consec-
utive real-life cohort of HF patients with depressed sys-
tolic function and echocardiographic studies performed 
over 15 years [10]. LVEF is a key predictor of survival and 
decreases over time are associated with reduced survival 
[17, 18]. The transient nature of LVEF recovery has been 
described previously in patients with depressed systolic 
function among T2D patients [17–20]. However, none 
of these studies compared LVEF trajectories along fol-
low-up between HF diabetic and non-diabetic patients. 
Cioffi et al. [19], in a small prospective short-term study 
that included patients with LVEF < 40% (22% had T2D), 
reported LVEF normalization in 22% of non-diabetic HF 
patients, whereas in diabetic population the LVEF recov-
ery only occurred in 4% of them. The present is the first 
to report the trajectory of LVEF over very long-term fol-
low-up in patients with T2D and HF compared to non-
diabetic HF patients.
Differences in long‑term LVEF trajectory between HF 
patients according to T2D status
The main finding of the current study was that LVEF 
trajectories in diabetic and non-diabetic patients were 
significantly different, as diabetic patients had a more 
pronounced inverted U shape of LVEF trajectory. This 
phenomenon suggests a component of diabetic cardio-
myopathy. Although the presence of diabetes-related 
cardiomyopathy is still controversial, a number of stud-
ies in both animals and humans have shown structural 
and functional changes of the diabetic heart, independ-
ent of comorbid conditions such as coronary artery dis-
ease, hypertension, or valvular heart disease [21]. It has 
been proposed that the development of diabetic cardio-
myopathy is likely to be multifactorial; several mecha-
nisms that include metabolic disturbances, myocardial 
fibrosis, small vessel disease, autonomic dysfunction, and 
insulin resistance have been implicated [8, 21]. Focus-
ing on structural alterations, the most prominent histo-
pathological finding in diabetic patients is fibrosis, which 
result in anatomic and physiological changes in the 
myocardium. Abnormalities in myocardial metabolism, 
such as impaired myocardial glucose uptake, have been 
described in ischemic diabetic experimental models [21]. 
The increased turnover of free fatty acids seen in diabetic 
patients may further impair myocardial glucose utiliza-
tion and may have other deleterious consequences such 
as changes in myocardial gene expression resulting in 
myocyte hypertrophy with impaired contractile function 
models [21, 22].
On the other hand, it is acknowledged that altered LV 
geometry may precede the development of T2D. A recent 
report found that LV concentric geometry determined 
by echocardiography and the severity of LV concen-
tricity evaluated as relative wall thickness (RWT) were 
associated with incident diabetes in the general popula-
tion [23]. Furthermore, long-term metformin exposure 
is associated with protective effects in terms of the inci-
dence of new-onset symptomatic HFpEF, LV diastolic 
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dysfunction and hypertrophy in patients with T2DM and 
hypertension, which might be beneficial for the delay of 
HFpEF progression [24].
Factors influencing LVEF trajectory in T2D patients
The interaction between LVEF trajectory and diabetes 
was remarkably centered in HF patients with ischemic 
etiology. We hypothesized that in ischemic diabetic HF 
patients, other mechanisms directly or indirectly related 
to diabetes such as specific diabetic cardiomyopathy 
may also be implicated. On the other hand, a close link 
between ischemic heart disease and diabetic myocardi-
opathy may exist. Coronary artery atherosclerosis, a phe-
nomenon associated with diabetes, is directly related to 
myocardial ischemia, and consequently, impaired myo-
cardial glucose uptake, increased oxidative stress, and 
vascular endothelial dysfunction, which may promote the 
progression of diabetic cardiomyopathy.
LVEF trajectories in diabetic patients are also influ-
enced by HF duration and sex. Regarding gender, bet-
ter LVEF dynamics were observed in women compared 
to men, regardless of the presence or absence of diabe-
tes. Men are at higher risk of developing left ventricular 
systolic dysfunction. The exact underlying mechanism is 
unclear, but sex-related differences in cardiac remodeling 
and the protective effects of estrogen against apoptosis 
may be among the explanations. In addition, we found 
an interaction between diabetes and LVEF trajectory 
in males; men with diabetes experienced a more pro-
nounced and earlier LVEF decline than those without 
diabetes. On the contrary we did not find any relationship 
between glycemic control and LVEF trajectory. There 
have been conflicting reports regarding the importance 
of glycemic control in patients with T2D and HF. Our 
results strongly suggest that other mechanisms rather 
than on diabetic status also may explain the differences 
in long-term LVEF trajectory. We must take into account 
the fact that comorbidities commonly seen in patients 
with diabetes, such as hypertension, dyslipidemia, and 
renal impairment, may accelerate the progression of car-
diac dysfunction towards advanced disease. In point of 
fact, the diabetic HF patients in our study had a higher 
percentage of hypertension and renal insufficiency than 
the non-diabetics.
Even considering a possible “survival effect,” very long-
term survival was accompanied by a progressive LVEF 
decline, which seemed to be earlier and more pronounced 
in diabetic patients. We usually continue neurohormonal 
blockade treatment in all patients irrespective of LVEF 
increase, as our data support that LVEF improvement 
represents myocardial remission rather than true myo-
cardial cure, and this issue might be especially important 
in diabetic patients. This might have important clinical 
implications, and further research is needed for a better 
understanding. Yet, a clear direction is lacking on what 
to do in patients who experience a decline in LVEF over 
time despite optimal medical treatment.
Outcomes in patients with and without T2D
Survival and event-free survival curves demonstrated 
that patients with T2D and ischemic heart disease exhib-
ited the greatest morbidity and mortality after 15 years of 
follow-up. However, the presence of diabetes was asso-
ciated with higher events, regardless of whether HF was 
of ischemic or non-ischemic origin. Some studies have 
already described that the prognostic impact of diabetes 
in patients with HF is markedly influenced by the under-
lying etiology and is particularly deleterious in ischemic 
heart disease models [4, 25–28]. In a large study pub-
lished by Johansson et  al. [28] that included 35.163 HF 
patients (24% had T2D), those with diabetes and ischemic 
heart disease had the highest mortality. Remarkably, in 
any of these studies, LVEF trajectory has been evaluated.
Future considerations
Finally, one important question to address in the future 
is how sodium glucose co-transporter 2 (SGLT2) inhibi-
tors affect LVEF trajectories in T2D with HF. SGLT2 
inhibitors act in renal glucose metabolism by inhib-
iting glucose reabsorption and inducing glycosuria, 
thereby reducing plasma glucose, blood pressure, and 
body weight [29]. Several studies in animal models have 
demonstrated their beneficial effects in left ventricu-
lar remodeling, cardiac fibrosis, and vascular dysfunc-
tion [30, 31]. Four large cardiovascular outcomes trials 
with SGLT2 inhibitors have shown important benefits 
in reducing HF hospitalization by about 30%, even in 
patients without T2D [32–35]. Several possible mecha-
nisms have been postulated to explain these benefits of 
SGLT2 inhibitors in HF, but they have not been con-
firmed [36]. We recently used artificial intelligence to 
describe that empagliflozin interacts and blocks the 
sodium-hydrogen exchanger co-transporter and might 
ameliorate cardiomyocyte cell death [37]. In our cohort, 
none of the patients were treated with SGLT2 inhibitors, 
so the results were not influenced by the possible effects 
of these drugs. On the other hand, in the Prove-HF trial 
[38], treatment with sacubitril-valsartan was associated 
with a significant improvement in LVEF during the first 
year of treatment. In our cohort only 3.8% received such 
treatment and none of them during the first year of fol-
low-up, so whether this treatment might influence LVEF 
long-term trajectory is not elucidated yet.
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Study limitations
This study had some limitations. Patients were classified 
into non-diabetic and diabetic subgroups according to 
their baseline diagnosis and no data on new-onset T2D 
diagnosis during follow-up were considered. We don’t 
have complete data of glycemic control of the whole 
period of the study and the whole cohort. HbA1c began 
to be routinely assessed around 2006. LVEF was assessed 
by transthoracic echocardiography in routine clinical 
care. However, in the current registry, all echocardio-
grams were scheduled prospectively and at pre-specified 
intervals and not at the discretion of the patient’s phy-
sician, and were not retrospectively analyzed. We 
acknowledge that intra- and inter-observer variability of 
echo-derived LVEF is ~ 5%. However, taking into account 
the large number of studies performed, we may assume 
that such variability was randomly distributed during 
follow-up. On the other hand, contrast echocardiogra-
phy, longitudinal and radial strain analyses, 3-D echo-
cardiography and cardiac magnetic resonance imaging 
would evaluate left ventricular function and volumes 
more precisely and may be superior in the evaluation of 
LV remodeling parameters, but they are not broadly used 
in clinical practice. As in all reported studies of variations 
in LVEF during follow-up, our analyses were performed 
in “completers,” that is, patients with both baseline and at 
least other echocardiography study available for analysis. 
We cannot fully exclude some bias in Loess spline curves 
due to dropout, as we could not statistically distinguish 
between autonomous time trends and pseudo upward 
trends because of successive drop out of fatalities with 
lower initial LVEF values. Missing data because of loss 
to follow-up was assumed to be random. Furthermore, 
Loess spline curve estimations at the end of follow-up 
were less robust due to the limited number of patients. 
The study cohort was a general HF population treated 
at a specific multidisciplinary HF clinic in a tertiary care 
hospital, with most patients referred from the cardiology 
department; thus, there was a predominance of relatively 
young men with HF of ischemic etiology, and an almost 
exclusively white population, so it may not be possible 
to fully extrapolate the findings to other populations. Of 
note, a common treatment protocol was applied to all 
patients, thereby limiting possible bias introduced by dif-
ferent management strategies or treatment protocols.
To provide more insight into understanding of the 
mechanisms involved in the “U-effect curve” observed 
in T2D patients, experimental models might be useful. 
These studies might contribute to assess the effect of 
hyperglycemia and insulin-resistance in the pathogenesis 
of diabetic cardiomyopathy.
Conclusions
LVEF in T2D with depressed systolic function showed 
an early improvement with a pronounced inverted U 
shape of trajectory and marked LVEF decline in the long 
term. This interaction was mainly observed in patients 
of ischemic etiology, in whom a component of diabetic 
cardiomyopathy might be present. In diabetic patients, 
LVEF trajectories varied upon disease modifiers such as 
HF etiology, HF duration, and sex.
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